Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

6.3K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K
Urinary Bladder01:23

Urinary Bladder

2.7K
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Commentary.

Urology practice·2025
Same author

Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group.

European urology oncology·2025
Same author

Challenging Cases in Urothelial Cancer: Case 33.

Bladder cancer (Amsterdam, Netherlands)·2024
Same author

Long-Term Recurrence Risk, Metastatic Potential, and Length of Cystoscopic Surveillance of Low-Grade Nonmuscle-Invasive Bladder Cancer.

The Journal of urology·2024
Same author

Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG).

European urology oncology·2024
Same author

Editorial Commentary.

Urology practice·2024
Same journal

Effective Mentorship in Urology Fellowship Training: Qualities, Models, and Equity.

Current urology reports·2026
Same journal

Management of Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis.

Current urology reports·2026
Same journal

Lower Urinary Tract Symptoms as an Indicator of Occult Neurologic Disease: A System-first Framework for Urologic Practice.

Current urology reports·2026
Same journal

Association Between Ambient Temperature and Urolithiasis: A Systematic Review and Meta-analysis.

Current urology reports·2026
Same journal

Is Open Partial Nephrectomy Still an Option in the Robotic Era?

Current urology reports·2026
Same journal

Artificial Intelligence in Urologic Documentation: A Review of Emerging Capabilities and the Ongoing Need for Human Oversight.

Current urology reports·2026
See all related articles

Related Experiment Video

Updated: Dec 17, 2025

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.9K

Ct2 Bladder Cancer.

Mark S Soloway1

  • 1Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. mssoloway@yahoo.com.

Current Urology Reports
|July 27, 2016
PubMed
Summary
This summary is machine-generated.

This case highlights a high-grade urothelial carcinoma initially presenting as gross hematuria. Subsequent resection revealed only focal carcinoma in situ, indicating successful treatment for bladder cancer.

Keywords:
Bladder cancerClinical stage T2N0M0Gross hematuriaUrothelial cancer

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.6K
An Orthotopic Model of Murine Bladder Cancer
09:07

An Orthotopic Model of Murine Bladder Cancer

Published on: February 6, 2011

16.3K

Related Experiment Videos

Last Updated: Dec 17, 2025

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.9K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.6K
An Orthotopic Model of Murine Bladder Cancer
09:07

An Orthotopic Model of Murine Bladder Cancer

Published on: February 6, 2011

16.3K

Area of Science:

  • Uro-oncology
  • Nephrology
  • Oncology

Background:

  • An 80-year-old male with a history of lung carcinoma, chronic obstructive pulmonary disease (COPD), and prostate cancer presented with gross hematuria.
  • Past treatments included chemotherapy, radiation, and surgery for lung cancer, and radical prostatectomy for prostate cancer.
  • Current renal function and cardiac status were normal, with mild COPD and good performance status.

Observation:

  • A 4-cm posterior bladder mass was identified on CT scan, with no hydronephrosis or enlarged lymph nodes.
  • Initial transurethral resection (TURBT) revealed a large, sessile, high-grade urothelial carcinoma invading the muscularis propria.
  • No lymphovascular invasion was noted on initial pathology.

Findings:

  • A repeat TURBT (reTURBT) was performed due to the initial findings.
  • The reTURBT identified only focal carcinoma in situ at the prior resection site.
  • Pathology from the reTURBT confirmed the absence of residual invasive carcinoma, with adequate muscle and fat margins.

Implications:

  • This case demonstrates a successful outcome following re-resection for high-grade urothelial carcinoma.
  • The findings suggest complete eradication of the tumor after extensive resection.
  • Further management strategies should consider the patient's history and the complete response observed.